335 related articles for article (PubMed ID: 19327818)
1. Splitomicin suppresses human platelet aggregation via inhibition of cyclic AMP phosphodiesterase and intracellular Ca++ release.
Liu FC; Liao CH; Chang YW; Liou JT; Day YJ
Thromb Res; 2009 Jun; 124(2):199-207. PubMed ID: 19327818
[TBL] [Abstract][Full Text] [Related]
2. A new insight of anti-platelet effects of sirtinol in platelets aggregation via cyclic AMP phosphodiesterase.
Liu FC; Liao CH; Chang YW; Liou JT; Day YJ
Biochem Pharmacol; 2009 Apr; 77(8):1364-73. PubMed ID: 19426675
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of antiplatelet activity of PC-09, a newly synthesized pyridazinone derivative.
Cherng SC; Huang WH; Shiau CY; Lee AR; Chou TC
Eur J Pharmacol; 2006 Feb; 532(1-2):32-7. PubMed ID: 16457809
[TBL] [Abstract][Full Text] [Related]
4. Splitomicin inhibits fMLP-induced superoxide anion production in human neutrophils by activate cAMP/PKA signaling inhibition of ERK pathway.
Liu FC; Day YJ; Liou JT; Yu HP; Liao HR
Eur J Pharmacol; 2012 Aug; 688(1-3):68-75. PubMed ID: 22634165
[TBL] [Abstract][Full Text] [Related]
5. Mode of action of 2-(diethylamino)-7-ethoxychromone on human platelets.
Leoncini G; Maresca M; Colao C; Buzzi E; Mazzei M
Cell Biochem Funct; 1991 Apr; 9(2):79-85. PubMed ID: 1718622
[TBL] [Abstract][Full Text] [Related]
6. Platelet lipoxygenase inhibitors attenuate thrombin- and thromboxane mimetic-induced intracellular calcium mobilization and platelet aggregation.
Nyby MD; Sasaki M; Ideguchi Y; Wynne HE; Hori MT; Berger ME; Golub MS; Brickman AS; Tuck ML
J Pharmacol Exp Ther; 1996 Aug; 278(2):503-9. PubMed ID: 8768697
[TBL] [Abstract][Full Text] [Related]
7. Effect of a potent cyclooxygenase inhibitor, 5-ethyl-4-methoxy-2-phenylquinoline (KTC-5), on human platelets.
Liao CH; Liao CH; Chang YL; Guh JH; Kuo SC; Huang LJ; Teng CM
J Pharm Pharmacol; 2002 Jul; 54(7):967-74. PubMed ID: 12162716
[TBL] [Abstract][Full Text] [Related]
8. [The studies on the mechanism of platelet activation induced by exogenous arachidonic acid with special reference to intraplatelet Ca2+ mobilization].
Koyama M
Hokkaido Igaku Zasshi; 1994 Jul; 69(4):1044-56. PubMed ID: 7959585
[TBL] [Abstract][Full Text] [Related]
9. Inhibitory effect of GBH on platelet aggregation through inhibition of intracellular Ca2+ mobilization in activated human platelets.
Park WH; Kim HK; Nam KS; Shon YH; Jeon BH; Moon SK; Kim MG; Kim CH
Life Sci; 2004 Nov; 75(25):3063-76. PubMed ID: 15474558
[TBL] [Abstract][Full Text] [Related]
10. Antiplatelet effect of sanguinarine is correlated to calcium mobilization, thromboxane and cAMP production.
Jeng JH; Wu HL; Lin BR; Lan WH; Chang HH; Ho YS; Lee PH; Wang YJ; Wang JS; Chen YJ; Chang MC
Atherosclerosis; 2007 Apr; 191(2):250-8. PubMed ID: 16797553
[TBL] [Abstract][Full Text] [Related]
11. 2-(2-Br-phenyl)-8-methoxy-benzoxazinone (HPW-RX2), a direct thrombin inhibitor with a suppressive effect on thromboxane formation in platelets.
Wu CC; Wang TW; Wang WY; Hsieh PW; Wu YC
Eur J Pharmacol; 2005 Dec; 527(1-3):37-43. PubMed ID: 16313903
[TBL] [Abstract][Full Text] [Related]
12. Effects of CI-930, a novel phosphodiesterase III inhibitor, on platelet aggregation and arachidonic acid metabolism.
Chen XS; Zeng HW; Jiang YY; Wan WQ; Long K
Zhongguo Yao Li Xue Bao; 1990 Jul; 11(4):338-43. PubMed ID: 1966575
[TBL] [Abstract][Full Text] [Related]
13. Direct evidence for the inhibition of platelet aggregation and release by intracellular cyclic AMP produced with a new photoactivatable derivative.
Blache D; Nargeot J; Nerbonne JM
Thromb Haemost; 1986 Apr; 55(2):168-72. PubMed ID: 3012817
[TBL] [Abstract][Full Text] [Related]
14. Inhibitory mechanisms of dihydroginsenoside Rg3 in platelet aggregation: critical roles of ERK2 and cAMP.
Lee WM; Kim SD; Park MH; Cho JY; Park HJ; Seo GS; Rhee MH
J Pharm Pharmacol; 2008 Nov; 60(11):1531-6. PubMed ID: 18957175
[TBL] [Abstract][Full Text] [Related]
15. Antiplatelet activity of carnosol is mediated by the inhibition of TXA2 receptor and cytosolic calcium mobilization.
Lee JJ; Jin YR; Lim Y; Hong JT; Kim TJ; Chung JH; Yun YP
Vascul Pharmacol; 2006 Sep; 45(3):148-53. PubMed ID: 16916624
[TBL] [Abstract][Full Text] [Related]
16. Antithrombotic activities of ferulic acid via intracellular cyclic nucleotide signaling.
Hong Q; Ma ZC; Huang H; Wang YG; Tan HL; Xiao CR; Liang QD; Zhang HT; Gao Y
Eur J Pharmacol; 2016 Apr; 777():1-8. PubMed ID: 26948317
[TBL] [Abstract][Full Text] [Related]
17. In vitro effect of a thymic epithelial culture supernate or thymosin fraction 5 on rabbit platelet aggregation and intracellular cyclic AMP levels.
Hashimoto S; Itoh Y; Kawaguchi A; Mizuno Y; Muraoka M; Tsuchiya M
J Cell Physiol; 1987 Dec; 133(3):499-506. PubMed ID: 2826498
[TBL] [Abstract][Full Text] [Related]
18. 2-Aminochromones block human platelet aggregation by inhibiting cyclic AMP-dependent phosphodiesterase leading to reduced platelet phospholipase C activity.
Benjamin CW; Lin AH; Morris J; Wishka DG; Gorman RR
J Pharmacol Exp Ther; 1993 Apr; 265(1):457-62. PubMed ID: 7682615
[TBL] [Abstract][Full Text] [Related]
19. Antiplatelet activity of epigallocatechin gallate is mediated by the inhibition of PLCgamma2 phosphorylation, elevation of PGD2 production, and maintaining calcium-ATPase activity.
Jin YR; Im JH; Park ES; Cho MR; Han XH; Lee JJ; Lim Y; Kim TJ; Yun YP
J Cardiovasc Pharmacol; 2008 Jan; 51(1):45-54. PubMed ID: 18209568
[TBL] [Abstract][Full Text] [Related]
20. Toborinone and olprinone, phosphodiesterase III inhibitors, inhibit human platelet aggregation due to the inhibition of both calcium release from intracellular stores and calcium entry.
Kageyama K; Mizobe T; Nozuchi S; Hiramatsu N; Nakajima Y; Aoki H
J Anesth; 2004; 18(2):107-12. PubMed ID: 15127258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
